Clinical trials · Baltimore, MD
Carcinoma clinical trials in Baltimore
We’re tracking 220 recruiting carcinoma studies with a site in or near Baltimore — including Phase 1, Phase 1/Phase 2, Phase 2 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies near Baltimore
- NCT02133196RecruitingPhase 2
T-cell treatment for lung cancer that has spread
This Phase 2 study tests a T-cell–based immunotherapy for people with metastatic non-small cell lung cancer that has grown despite prior treatment. It may help your immune system recognize and fight your cancer using cells made from your tumor.
Bethesda, MarylandAges 18–72 - NCT05687149Recruiting
Study of mouth and throat cancer patterns in Fanconi anemia
This study looks at how squamous cell carcinoma (a type of cancer) naturally develops over time in people with Fanconi anemia. It may help doctors better recognize warning signs and plan care in the future.
Bethesda, MarylandAges 8–90 - NCT07509034RecruitingPhase 1
Targeted immune cells for recurrent small cell lung cancer
This trial tests a special immune cell therapy (CAR T cells) that targets a protein called B7-H3 on your cancer cells. It is for people with small cell lung cancer or similar neuroendocrine cancers that have returned or not responded to standard treatments.
Bethesda, MarylandAges 18–120 - NCT06503146RecruitingPhase 2
New imaging tracer for detecting various cancers
This trial tests a new imaging agent, [18F]FAPI-74, which might help detect certain cancers more clearly. The scan looks for a protein called fibroblast activation protein (FAP) that is often found in tumors. If you have one of the listed cancers and are about to start treatment, this study could help doctors see where the cancer is and how it responds to therapy.
Bethesda, MarylandAges 18–120 - NCT05521698RecruitingPhase 1
Bicalutamide for early-stage bladder cancer
This trial tests whether the drug bicalutamide can help men with early-stage (non-invasive) bladder cancer, which has not grown into the bladder muscle. It is given before surgery to see if it can reduce the chance of the cancer coming back. Participants will be randomly assigned to receive bicalutamide or a placebo before their scheduled surgery.
Bethesda, MarylandAges 18 years+ - NCT05665361RecruitingPhase 1/Phase 2
Testing palbociclib plus sasanlimab for advanced kidney cancers
This study tests a combination of two medicines—palbociclib and sasanlimab—in people with advanced clear cell or papillary kidney cancer. It’s mainly designed to check safety (and early signs of how well the treatment may work) in these cancer types.
Bethesda, MarylandAges 18–100 - NCT06157151RecruitingPhase 2
New drug plus pembrolizumab for advanced cervical cancer
This trial tests a new experimental drug, PRGN-2009, combined with the immunotherapy pembrolizumab (Keytruda) for people with HPV-related cervical cancer that has come back or spread. It is for those who have already tried pembrolizumab and are looking for another option.
Bethesda, MarylandAges 18 years+ - NCT06171750RecruitingPhase 1
Study of ANK-101 for advanced solid tumors
This trial tests a new drug, ANK-101, injected directly into tumors to help fight advanced solid tumors that have spread or can't be treated with standard therapies. It may be an option if you have a tumor that can be reached for injection.
Bethesda, MarylandAges 18 years+ - NCT06161532RecruitingPhase 2
Sacituzumab govitecan with or without atezolizumab for rare GU cancers
This trial is testing a drug called sacituzumab govitecan, sometimes combined with atezolizumab (an immunotherapy), for rare cancers of the bladder, urinary tract, kidney, or penis. The goal is to see if these treatments work well for people whose cancers have not responded to other options.
Bethesda, MarylandAges 18–120 - NCT06161545RecruitingPhase 2
Immunotherapy before surgery for head and neck cancer
This trial tests a combination of two immunotherapy drugs (pembrolizumab and N-803) with or without special immune cells (PD-L1 t-haNK cells) before surgery for head and neck cancer. The goal is to see if this treatment can shrink the cancer or improve the outcome after surgery.
Bethesda, MarylandAges 18–120 - NCT06176989RecruitingPhase 2
Enasidenib for IDH2-mutated sinonasal and skull base tumors
This trial tests an oral targeted therapy called enasidenib for people with rare head and neck cancers that have an IDH2 gene mutation. The goal is to see if this drug can shrink or slow the growth of these tumors.
Bethesda, MarylandAges 18–120 - NCT05237934Recruiting
Study collects tissue samples and tracks neuroendocrine tumors
This study looks at neuroendocrine tumors by collecting tissue (when available) and tracking how the disease behaves over time. It may help researchers better understand these cancers, including rare cases of adrenocortical cancer.
Bethesda, MarylandAges 18–120 - NCT04181060RecruitingPhase 3
Osimertinib alone or with bevacizumab for EGFR-mutant lung cancer
This Phase 3 trial tests whether starting osimertinib with or without bevacizumab helps people with advanced EGFR-mutant lung cancer live longer and control the cancer better. Your EGFR mutation test result and past treatments are key to whether you can join.
Bethesda, MarylandAges 18 years+ - NCT06406465RecruitingPhase 2
Belinostat trial for neuroendocrine cancer based on genetics
This trial tests a drug called belinostat, possibly combined with other drugs, based on your genetic makeup. It aims to find the right dose for people with a rare and aggressive neuroendocrine cancer that started outside the lungs.
Bethesda, MarylandAges 18–120 - NCT06479811RecruitingPhase 1
Radioactive drug for advanced neuroendocrine and other cancers
This early-stage trial tests a new radioactive drug (called [212Pb]VMT-Alpha-NET) that targets a marker on certain cancer cells. It may help shrink or slow the growth of tumors that have spread or can't be removed, and it's being studied for several cancer types, including neuroendocrine tumors, small cell lung cancer, kidney cancer, and some head and neck cancers.
Bethesda, MarylandAges 18–120 - NCT04510597RecruitingPhase 3
Immunotherapy plus surgery versus immunotherapy alone for kidney cancer
This study tests whether adding surgery to remove the kidney improves outcomes compared with continuing immunotherapy without surgery. It is for people with metastatic kidney cancer whose disease has not worsened after initial immunotherapy.
Washington D.C., District of ColumbiaAges 18 years+ - NCT07046832Enrolling by invitation
Augmented reality needle guidance for soft tissue biopsy
This trial tests a new augmented reality system that helps guide the needle during a soft-tissue biopsy. It may make the procedure more accurate and easier for your doctor.
Washington D.C., District of ColumbiaAges 18 years+ - NCT06806930RecruitingPhase 2
Predicting response to hormone therapy before breast cancer surgery
This trial tests whether we can predict how well hormone therapy works before surgery for early-stage breast cancer. It may help women with estrogen receptor-positive, HER2-negative or HER2-low breast cancer avoid or tailor treatments.
Washington D.C., District of ColumbiaAges 21 years+ - NCT07227168RecruitingPhase 1
Study of STRO-004 for advanced solid tumors
This trial tests a new drug called STRO-004 for people with advanced solid tumors (cancers that have spread or come back). It aims to see if the drug is safe and effective for those who have already tried other treatments.
Washington D.C., District of ColumbiaAges 18 years+ - NCT06225427RecruitingPhase 1
Gilteritinib for advanced ALK-positive lung cancer
This trial tests a drug called gilteritinib for people with a specific genetic type of lung cancer (ALK-positive) that has spread and has been treated before. You may be eligible if you have already tried at least one targeted therapy, and your cancer is still growing.
Washington D.C., District of ColumbiaAges 18 years+ - NCT07644598RecruitingPhase 2
Targeted Radiation Therapy for Low to Intermediate Risk Prostate Cancer
This study tests a new radiation treatment approach that uses MRI imaging to target specific tumor areas within the prostate while reducing radiation to healthy tissue. It may help patients with early-stage prostate cancer get effective treatment with fewer side effects.
Washington D.C., District of ColumbiaAges 18 years+ - NCT03556228RecruitingPhase 1/Phase 2
Tested medicine for tumors with TrkA changes, alone or with pembrolizumab
This early-phase study tests VMD-928, a targeted cancer medicine, for cancers that have TrkA-related tumor changes. It may be given by itself or with pembrolizumab to see if it can shrink tumors when standard treatments have not worked.
Washington D.C., District of ColumbiaAges 18–80 - NCT06931340RecruitingPhase 3
Adding chemo to hormone therapy for advanced prostate cancer
This trial is for men with metastatic prostate cancer that has already spread beyond the pelvis. It tests whether adding a chemotherapy drug (docetaxel) to the usual hormone therapy plus apalutamide can help control the cancer better than hormone therapy alone.
Washington D.C., District of ColumbiaAges 18 years+ - NCT06758401RecruitingPhase 3
Study of combination treatment for advanced lung cancer with high PD-L1
This trial tests a new combination of two medicines (sigvotatug vedotin and pembrolizumab) for people with a type of lung cancer called non-small cell lung cancer (NSCLC) that has high levels of a protein called PD-L1. The treatment is designed to help your immune system fight the cancer more effectively, and this study aims to see how well it works.
Washington D.C., District of ColumbiaAges 18 years+
Hear when a new Carcinoma trial opens near Baltimore, MD
We’ll email you when one opens near Baltimore, MD — at most once a week, no account needed, unsubscribe anytime.
Carcinoma trials in other cities
Where these studies are running near Baltimore
Institutions with a site for the recruiting carcinoma studies listed above.
- National Institutes of Health Clinical Center · 11 studies
- MedStar Washington Hospital Center · 2 studies
- George Washington University
- George Washington-Medical Faculty Associates
- Georgetown Lombardi Comprehensive Cancer Center
- Georgetown University
- Georgetown University Medical Center
- MedStar Georgetown Hospital
What taking part in a carcinoma study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Looking wider? See all recruiting carcinoma studies in Maryland.
Common questions
- Are there carcinoma clinical trials near Baltimore?
- Yes. We're currently tracking 220 recruiting carcinoma studies with a site near Baltimore, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a carcinoma study near Baltimore?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Baltimore to take part?
- Not necessarily. These studies have a site near Baltimore, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a carcinoma trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New carcinoma studies open near Baltimore regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.